Seres Therapeutics stockholders approve 900k share increase to 2025 Incentive Award Plan

Seres Therapeutics, Inc.

Stockholders approved amendment to 2025 Incentive Award Plan, increasing shares available by 900,000.
Three Class II directors elected: Stephen A. Berenson, Claire M. Fraser, Ph.D., Richard N. Kender.
Advisory vote on executive compensation passed with 3,374,813 for, 620,353 against.
Ratification of PwC as auditor for FY2026 approved with 4,542,915 for, 267,601 against.
Meeting had 51.75% quorum (4,985,176 shares represented).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.